The SILCS diaphragm is a new, reusable, single-size cervical barrier device that is designed to offer the same barrier protection as a standard diaphragm with improved user acceptability.
FDA Approval of a New Female Condom
Reuters (March 11, 2009) reports that a new, less expensive version of the Female Health Company's female condom was approved for marketing in the United States and that the decreased price and softer design (allowing for quieter use) may attract more women in the United States. Most other countries have already adopted the new synthetic rubber version, called the FC2, but FDA approval of the new, less expensive product will allow the US Agency for International Development (USAID) to buy it and potentially increase availability abroad, Reuters reports (December 11, 2008) . Reuters (December 11, 2008) reports that the FDA panelists recognized the potential of the female condom to provide women more control over their ability to protect themselves against pregnancy and HIV infection. The Female Health Company is currently searching for marketing partners in the US (Reuters, December 11, 2008) . You can read the March 11 Reuters article online here: http://www.reuters.com/article/ latestCrisis/idUSN10547381.
Background:
The SILCS diaphragm is a new, single-size contraceptive diaphragm. The objective of this crossover pilot study was to assess the fit and acceptability of the SILCS diaphragm compared to the Ortho ALL-FLEX® diaphragm to validate the product design among parous women in a low-resource setting.
Study Design: Sexually active couples not at risk of pregnancy and at low risk of sexually transmitted infection were recruited and randomly assigned to one of two groups to determine order of device use. Couples used each device four times and provided feedback on key performance indicators via product-use questionnaires, a simple coital log, and a gender-specific debriefing interview.
Results: Twenty couples provided data on a total of 160 product uses (80 for each device). Couples indicated that both diaphragms were acceptable with respect to ease of use, comfort, and satisfaction with sex. At the end of the study, 19 of 20 women and 15 of 20 men reported preferring the SILCS diaphragm over the Ortho diaphragm (p≤.01 for both).
Conclusion: Short-term acceptability of the SILCS and Ortho diaphragms during use was comparable, although overall both women and men preferred the SILCS diaphragm over the Ortho diaphragm. Acceptance of diaphragms in general, and the SILCS diaphragm in particular, is likely among couples willing to use a barrier method.
Comparative acceptability of the SILCS and Ortho ALL-FLEX® diaphragms among couples in the Dominican Republic. couples completed a baseline cycle and at least one test cycle, 12 couples completed a baseline cycle and two test cycles and 8 couples completed a third test cycle with the polymer spring prototype. Sperm was detected in the vaginal pool in all completed test cycles. The SILCS metal spring diaphragms used with N-9 gel reduced the average number of progressively motile sperm per high power field in the cervical mucus from a baseline of 12.5 to 0, while use of this device with lubricant reduced the number to 0.5. The SILCS polymer spring diaphragm used with N-9 performed the same as the metal spring used with N-9.
Conclusion:
The SILCS diaphragm used with N-9 gel performed well. It is likely that the SILCS diaphragm will give acceptable results in a contraceptive effectiveness study but that adjunctive use of a chemical barrier such as N-9 gel will be necessary for it to be most effective.
Background and methodology:
The diaphragm, once the most commonly used female contraceptive method, is being re-evaluated for prevention against some sexually transmitted infections (STIs), including HIV. However, provider views about this prescription-based method are poorly understood. Using expert panels, this study aimed to identify facilitative strategies to increase diaphragm use. The nominal group technique (NGT) was employed using a novel web-based interface to systematically elicit and prioritise responses to a specific question about what can be done to encourage providers to recommend diaphragm use. Two NGT sessions were convened with 15 geographically dispersed panelists who had extensive knowledge and experience with the diaphragm. Participants were identified using purposeful and snowball sampling. perceived as relatively more important (67% of the total available votes). Panel 2 identified 31 strategies, nine of which accounted for 77% of the votes. Both sessions highlighted that to make the diaphragm a more plausible option, educational materials and tools are needed to better inform providers and patients about the method and its specific advantages.
Conclusions:
The enhanced, Internet-based NGT offers the family planning and reproductive health care field a powerful and inexpensive tool for systematically collecting and analysing expert opinion. Results are being used to develop a questionnaire to further examine strategies that may help promote diaphragm use and to refine ideas for intervention design. This will facilitate method reintroduction, if the diaphragm is proven effective against STIs/HIV, especially when used with a microbicide.
Objectives:
We evaluated the efficacy of skills training designed to increase female condom use among women.
Methods:
We conducted a randomized controlled trial of 409 women, recruited from family planning clinics in northern California, who were randomly assigned to the experimental 4-session female condom skills training intervention or the comparison 4-session women's general health promotion intervention. Participants received condom use instructions at baseline and male and female condoms during the study. They completed audio computer -assisted self-interviews at baseline and at 3 and 6 months.
The efficacy of female condom skills training in HIV risk reduction among women: a randomized controlled trial. Choi KH, Hoff C, Gregorich SE, Grinstead O, Gomez C, Hussey W. Results: At 3 and 6 months, women in the experimental group were more likely than those in the comparison group to have used the female condom at least once in the prior 3 months. The increase in the percentage of sexual acts protected by female condoms from baseline to the 6-month follow-up was greater for the experimental group. The percentage of sexual acts during which any condom was employed was higher in the experimental group at 6 months. There were no group differences in male condom use.
Conclusions: Outcomes suggest that skills training can increase female condom use and protected sexual acts without reducing male condom use among women.
Universal Access to Female Condoms Joint Programme
The year 2008 marked the 15th anniversary of the availability of the female condom as a tool in the fight against growing rates of HIV infection, yet female condoms remain only a small fraction of the global condom supply. for All on April 1st will feature stories of women who have struggled to get the health care that they and their families need, and make the connection between these personal experiences and policy solutions. The Strategy Conference on April 2nd will move from women's stories about the health system to strategy about how to achieve real reforms that address the problems women have identified. National health policy experts will give an update on the progress of health reform in Washington. We will end the day with an agenda for action. 
What are cervical barriers?
Most people think of cervical barriers primarily as the diaphragm and cervical cap, but a broader definition would encompass Lea's shield, female and male condoms, the sponge, and microbicides. For more information about the range of cervical barrier methods, go to http://www.cervicalbarriers.org/information/methods.cfm.
Mission of CBAS
Established in 2004, the Cervical Barrier Advancement Society (CBAS) aims to raise the profile of cervical barrier methods for pregnancy prevention and provide information about research on the potential of cervical barriers to prevent sexually transmitted infections, including HIV.
Membership
CBAS membership is free and open to all who are interested in joining. CBAS's goal is to create an international, professional networking organization including clinical and social science research groups, academic institutions, advocacy groups, trade associations, and pharmaceutical, biotech, and medical device companies. As a member, you will have the opportunity to network and collaborate with other professionals in the field; keep abreast of new research; share information and ideas; and receive a semi-annual newsletter. Upcoming events
CBAS

